Please assess the completion status of the following clinical trial:

Trial Title: DP-R213 Phase 1 Pharmacokinetics Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IBW ±20%~* Signed the informed consent form prior to the study participation~Exclusion Criteria:~* Clinically significant disease~* Previously donate whole blood within 2 months or component blood within 1 month~* Clinically significant allergic disease~* Taken IP in other trial within 3 months~* An impossible one who participates in clinical trial by investigator's decision including laboratory test result

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RT group (Type: EXPERIMENTAL): combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
- TR group (Type: EXPERIMENTAL): combination dose of Raloxifene and Cholecaliferol and DP-R213 in order

Based on this trial design, predict the completion outcome and termination type (if applicable).